此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Effects of Hormone Replacement Therapy on Arthralgia in Postmenopausal Women

2019年10月11日 更新者:Hospital de Clinicas de Porto Alegre

Effects of Hormone Replacement Therapy on Arthralgia in Postmenopausal Women: a Randomized, Double-blind Controlled Trial

Arthralgia has been a common complaint in postmenopausal period which seems to be involved with estrogen depletion, although, its pathophysiology isn´t completely clarified. It seems to relate with the level of physical activity, climacteric symptoms and pain catastrophizing. In view of the multiple dimensions involved in arthralgia in postmenopausal women which characterize it as a complex phenomenon, this study aims to describe the effects of hormone replacement therapy in women aged between 45 and 55 years, considering estrogen as a possible anti-nociceptive factor.

研究概览

详细说明

This study is a randomized double-blind controlled clinical trial with postmenopausal women aged between 45 and 55 years with chronic arthralgia related to climacteric. They will be evaluated climacteric symptoms, pain intensity, level of physical activity, pain catastrophising, depression, anxiety, quality of sleep and quality of life. The volunteers will be randomized, in the proportion 1:1, to treatment with either 0,625 mg conjugated equine estrogen, via oral administration, for 12 weeks or placebo, via oral administration, for 12 weeks. The randomization will be performed by a computer-generated random numbers list. The investigators will be blinded until completion of 12 weeks. Evaluation of climacteric symptoms, pain intensity, level of physical activity, pain catastrophising, depression, anxiety, quality of sleep and quality of life will be performed in the hospital at baseline, 1, 2, 3, 6 months and 15 days. In each visit, participants will be evaluated about adverse effects such as diarrhea, nausea and vomit.

研究类型

介入性

注册 (预期的)

72

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Rio Grande Do Sul
      • Porto Alegre、Rio Grande Do Sul、巴西
        • 招聘中
        • Comitê de Ética em Pesquisa do Hospital de Clínicas de Porto Alegre
        • 接触:
          • Maria Celeste Osório Wender, Ph.D
          • 电话号码:+55513359-8117
          • 邮箱:mceleste@ufrgs.br
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

45年 至 55年 (成人)

接受健康志愿者

是的

有资格学习的性别

女性

描述

Inclusion Criteria:

  • age between 45 and 55 years
  • chronic arthralgia related to climacteric
  • regular mammography and pap smear test in the last twelve months
  • availability to attend hormone replacement therapy
  • maximum of ten years of amenorrhea according to the criteria of Stages of Reproductive Aging Workshop (STRAW)
  • without use of hormone replacement therapy, at least, previous six months
  • no contraindication to hormone replacement therapy (current or past of breast and / or cervical cancer, severe current or recent heart disease, thromboembolism, hypertension with no control, metabolic diseases (but stable thyroid disease) and endometrial hyperplasia to be enlightened
  • Informed consent

Exclusion Criteria:

  • autoimmune diseases
  • visceral pain (chronic pelvic pain, dyspareunia, irritable bowel syndrome)
  • systemic diseases (rheumatic, neurological, oncology, sexually transmitted infection)
  • body mass index of 30 or greater
  • soy diet
  • abuse of alcohol and drugs
  • large surgeries

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Conjugated Equine Estrogen

Thirty-six healthy postmenopausal women aged between 45 and 55 years will receive 0,625 mg/day conjugated equine estrogen (CEE) for 12 weeks. These 1 active pill containing conjugated equine estrogen, 0,625 mg will be provided by a laboratory with no trademark identification.

The bottles will be numbered in code by a pharmaceutist not involved directly in study and they will donated to volunteers.

During the intervening period, use of conjugated equine estrogen, there will be blinding. After this phase, blinding will be interrupted in order to identify volunteers who used the active drug.

Use of conjugated equine estrogen for 12 weeks. Adherence will be monitored during periodical hospital visits in order to receive pills.
其他名称:
  • Drug active
安慰剂比较:Placebo

Thirty-six healthy postmenopausal women aged between 45 and 55 years will receive placebo pills, identical in size, shape and color to the active drug, via oral administration, for 12 weeks.

The bottles, without trademark identification, will be numbered in code by a pharmaceutist not involved directly in study and they will donated to volunteers.

During the intervening period, use of placebo, there will be blinding. After this phase, blinding will be interrupted in order to identify volunteers who used the active drug and placebo.

Use of placebo for 12 weeks. Adherence will be monitored during periodical hospital visits in order to receive pills.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Arthralgia
大体时间:6 months
Arthralgia´ll be measured by numeric scale (0-10).
6 months

次要结果测量

结果测量
措施说明
大体时间
Climacteric symptoms
大体时间:6 months
Climacteric symptoms´ll be evaluated by Menopause Rating Scale - Brazilian Version. The score increases point by point with increasing severity of subjectively perceived symptoms in each of the 11 items.
6 months
Level of physical activity
大体时间:6 months
Level of physical activity´ll be evaluated by International Physical Activity Questionnaire - Brazilian Version whose three levels of physical activity are low, moderate and high.
6 months
Pain Catastrophizing
大体时间:6 months
Pain Catastrophizing´ll be evaluated by Pain Catastrophizing - Brazilian Version into three subscales being magnification, rumination, and helplessness. The higher the score, the more catastrophizing thoughts are present.
6 months
Health-related quality of life
大体时间:6 months
Quality of life´ll be evaluated by Women´s Health Questionnaire - Brazilian Version (somatic symptoms, depressed mood, cognitive difficulties, anxiety and fear, sexual functioning, vasomotor symptoms, sleep problems, menstrual problems, and self-perceived attraction). The higher the score, the more pronounced the suffering and dysfunction.
6 months
Depression
大体时间:6 months
Depression´ll be evaluated by Beck Depression Inventory - Brazilian Version. The standard cut-off scores are minimal, mild, moderate and severe depression.
6 months
Anxiety
大体时间:6 months
Anxiety´ll be evaluated by Beck Anxiety Inventory - Brazilian Version. The standard cut-off scores are minimal, mild, moderate and severe depression.
6 months
Quality of sleep
大体时间:6 months
Quality of sleep´ll be evaluated by Pittsburgh Sleep Quality Index - Brazilian Version. Lower scores denote a healthier sleep quality.
6 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Maria Celeste Osório Wender, Ph.D、Hospital de Clinicas de Porto Alegre

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2017年3月1日

初级完成 (预期的)

2019年12月2日

研究完成 (预期的)

2020年12月31日

研究注册日期

首次提交

2016年6月9日

首先提交符合 QC 标准的

2016年7月15日

首次发布 (估计)

2016年7月20日

研究记录更新

最后更新发布 (实际的)

2019年10月14日

上次提交的符合 QC 标准的更新

2019年10月11日

最后验证

2019年1月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅